Figure 4 :Clinical outcomes of COVID-19 in autoimmune rheumatic diseases. (A) Hospitalization rates. (B) Mortality. (C) ICU admission rate.
The ICU admission rate of COVID-19 patients with ARDs was 0.077(95%CI:0.051-0.107)(Figure 4). ICU admission rates of RA, SLE and CTD, PsA were 0.117(95%CI:0.066-0.168), 0.218(95%CI:0.099-0.361) and 0.054(95%CI:0.028-0.081), 0.046(95%CI:0.007-0.084)(Figure p9). The mortality due to COVID-19 in ARD patients was 0.073(95%CI:0.046-0.104)(Figure 4). Mortality rates of RA, SLE, CTD and vasculitis were 0.049(95%CI:0.025-0.079), 0.146(95%CI:0.051-0.241), 0.058(95%CI:0.016-0.120), and 0.224(95%CI:0.179-0.269). The mortality rates in AS, SSC, and gout were 0.000(95%CI:0.000-0.018), 0.007(95%CI:0.000-0.241), and 0.099(95%CI:-0.138 to 0.336), which were all not statistically significant(Figure p10). SLE patients had the highest ICU admission rate, and vasculitis patients had the highest mortality. In contrast, PsA patients had the lowest ICU admission rate, and RA patients had the lowest mortality.